Company intelligence / Profile preview
Teika Pharmaceutical
Toyama, Toyama, Japanteika.co.jp ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Teika Pharmaceutical has multiple approved products in Japan, especially for ophthalmic and topical indications, and also has preclinical pipeline activity in gene therapy for ophthalmic diseases, through partnerships[4][5].
- Therapeutic areas
- OphthalmologyInfectious DiseasesNeurologyDermatology
- Modalities
- Small moleculeGene therapyProteinBiologicPeptides
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Nippon Medical School (gene therapy research)
Beyond the preview
Go deeper on Teika Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Teika Pharmaceutical.